CGTX · Cognition Therapeutics Inc
United States · RS rating 12 · As of 2026-11-03
| Price | 0.70 USD |
|---|---|
| 1-day change | -1.5% |
| RS rating (overall / 1M / 3M / 12M) | 12 / 16 / 17 / 16 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 15 / 4 / 32 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | – |
| Sales growth Q/Q | – |
| Distance from 52-week high | +61.1% |
| Market cap (USD) | $112.6M |